| Dap Health-stonewall Community Health Center | |
|
68555 Ramon Rd Ste 201-207 Cathedral City CA 92234-3310 | |
| (619) 873-3538 | |
| Not Available |
| Full Name | Dap Health-stonewall Community Health Center |
|---|---|
| Speciality | Clinic/Center |
| Location | 68555 Ramon Rd Ste 201-207, Cathedral City, California |
| Authorized Official Name and Position | Judy Stith (CHIEF ADMINISTRATIVE OFFICER) |
| Authorized Official Contact | 7603232118 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Dap Health-stonewall Community Health Center 1695 N. Sunrise Way Palm Springs CA 92262 Ph: (760) 323-2118 | Dap Health-stonewall Community Health Center 68555 Ramon Rd Ste 201-207 Cathedral City CA 92234-3310 Ph: (619) 873-3538 |
| NPI Number | 1386180404 |
|---|---|
| Provider Enumeration Date | 01/12/2017 |
| Last Update Date | 11/28/2023 |
| Medicare PECOS PAC ID | 1759299944 |
|---|---|
| Medicare Enrollment ID | O20171211001341 |
News Archive
Crescent Healthcare today announced a planned expansion of their east coast operations in 2011. They signed a lease to open an infusion pharmacy in Totowa, New Jersey, central to providing immune globulin therapies and services to current patients in Massachusetts, Maryland, New York, New Jersey, Pennsylvania, Connecticut, Delaware, District of Columbia, and Rhode Island.
AssureRx Health, Inc. today announced the closing of a $12.5 million Series C financing. The personalized medicine company, which provides clinically-relevant information to help physicians select the right drug for individual neuropsychiatric patients, will use the funds to increase commercial activities for its two flagship pharmacogenomic products, GeneSightRx Psychotropic and GeneSightRx® ADHD, as well as next generation product development activities.
Santarus, Inc., a specialty biopharmaceutical company, today announced that its collaboration partner, Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA (SIX: COPN), has completed enrollment of 514 patients in the European Phase III clinical trial to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis.
Merck, known as MSD outside the United States and Canada, today announced results from a Phase II trial for odanacatib, an investigational cathepsin K (cat-K) inhibitor in development for the treatment of osteoporosis in post-menopausal women.
NanoPass Technologies Ltd., a pioneer in intradermal delivery solutions for immunotherapies, announced today that it has entered into a clinical supply and support agreement for the supply of MicronJet600, its microneedle delivery device, for use with Immune Design's oncology immunotherapy products from its ZVex discovery platform.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386180404 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QF0400X | Clinic/center - Federally Qualified Health Center (fqhc) | (* (Not Available)) | Primary |
News Archive
Crescent Healthcare today announced a planned expansion of their east coast operations in 2011. They signed a lease to open an infusion pharmacy in Totowa, New Jersey, central to providing immune globulin therapies and services to current patients in Massachusetts, Maryland, New York, New Jersey, Pennsylvania, Connecticut, Delaware, District of Columbia, and Rhode Island.
AssureRx Health, Inc. today announced the closing of a $12.5 million Series C financing. The personalized medicine company, which provides clinically-relevant information to help physicians select the right drug for individual neuropsychiatric patients, will use the funds to increase commercial activities for its two flagship pharmacogenomic products, GeneSightRx Psychotropic and GeneSightRx® ADHD, as well as next generation product development activities.
Santarus, Inc., a specialty biopharmaceutical company, today announced that its collaboration partner, Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA (SIX: COPN), has completed enrollment of 514 patients in the European Phase III clinical trial to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis.
Merck, known as MSD outside the United States and Canada, today announced results from a Phase II trial for odanacatib, an investigational cathepsin K (cat-K) inhibitor in development for the treatment of osteoporosis in post-menopausal women.
NanoPass Technologies Ltd., a pioneer in intradermal delivery solutions for immunotherapies, announced today that it has entered into a clinical supply and support agreement for the supply of MicronJet600, its microneedle delivery device, for use with Immune Design's oncology immunotherapy products from its ZVex discovery platform.
› Verified 4 days ago
Borrego Community Health Foundation Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 69195 Ramon Rd Ste C3, Cathedral City, CA 92234 Phone: 855-436-1234 | |
Dap Health - Centro Medico Cathedral City - 69175 Ramon Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 69175 Ramon Rd Ste D-4, Cathedral City, CA 92234 Phone: 760-321-6776 Fax: 760-321-4036 | |
Vivien Pacold, M.d., Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 68100 Ramon Rd, C-5, Cathedral City, CA 92234 Phone: 760-321-6068 Fax: 760-770-6789 | |
Dap Health - Centro Medico Cathedral City - Dental Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 69195 Ramon Rd Ste C3, Cathedral City, CA 92234 Phone: 855-436-1234 | |
Desert Aids Project Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 69175 Ramon Rd, Cathedral City, CA 92234 Phone: 760-323-2118 | |
Desert Aids Project Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 69175 Ramon Rd Bldg A, Cathedral City, CA 92234 Phone: 760-323-2118 |